Compare Amgen, Inc. (AMGN) vs Colgate-Palmolive Company (CL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Colgate-Palmolive Company — how do they compare? Amgen, Inc. trades at $362.12 (market cap $196.12B), while Colgate-Palmolive Company trades at $92.91 (market cap $73.81B). The key difference: Amgen, Inc. is far larger — about 2.7× Colgate-Palmolive Company's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | CL | |
|---|---|---|
Market Cap | $196.12B | $73.81B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $99.14 |
52-Week Low | $271.18 | $74.98 |
Enterprise Value | $241.41B | $80.45B |
Dividend Yield | 2.77% | 2.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Colgate-Palmolive (CL) trades at $92.24, up 1.35% on the day, reflecting strong momentum with a bullish technical signal and consistent earnings beats. The company maintains robust profitability with a 60.06% gross margin and 10.04% net income margin, though its P/E of 35.75 and P/B of 509.03 indicate premium valuation. Recent news highlights its status as a Dividend King with a 64-year streak, supported by stable cash flow from operations of $4.20B in 2025.
Outlook remains positive with analyst consensus target of $95.56, but risks include North American segment softness and inflationary pressures. The stock offers income stability through dividends, yet high valuation multiples may limit near-term upside absent accelerated growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →
